Recursion Pharmaceuticals (RXRX) Stock Price
$5.73 0%
to add to portfolio
AI Score
-
Alternative
7 -
Fundamental
1 -
Technical
5
Our AI score evaluates a company's performance on a scale from 0 to 10 by analyzing alternative data points — web traffic, app downloads, job postings, etc - along with financial health and technical signals. Scores below 4 project bearish performance, while scores above 6 project bullish performance.
Sign up to get access to more historical data and insights on Recursion Pharmaceuticals, AI stock picks, stock alerts and much more.
RXRX AI Stock Analysis
Financial Performance
The financial performance of Recursion Pharmaceuticals appears to be struggling. The company's revenue has declined by -82.7% from the previous quarter and -67.3% year over year, indicating a significant decrease in sales or services. The gross profit was -$8.3M, reflecting an increase in cost of goods sold or a decrease in sales volume. The operating income also showed a large decline, down by -86.8% from the previous quarter and down by -90.7% year over year, suggesting that the firm is not efficiently managing its operating costs.
Stock Price
The stock price for Recursion Pharmaceuticals has been trending downwards with a loss of -9.8% in the last month and -29.4% YoY, currently trading at $5.73 which is below its 200-day moving average of $6.88, implying bearish sentiment among investors.The RSI value stands at 56.41 showing neither overbought nor oversold conditions.
Alternative Data Signals
Website traffic trends show a decrease of -11.9%, which may suggest less interest or engagement with the company online.Job postings have decreased significantly by -37.% MoM and by-69% YoY indicating potential hiring freeze or layoffs.Positive business outlook reported by employees shows slight improvement MoM but overall decline YoY.Social media followers on Twitter have seen substantial growth over last 90 days while Facebook followers growth remains moderate.This mixed social media trend does not provide a clear signal towards investor sentiment towards the company.
Conclusion
In conclusion,the analysis suggests bearish sentiment for Recursion Pharmaceuticals' stock considering declining revenues,gross profits,and operating income along with downward trending stock price and mixed alternative data signals.
Recursion Pharmaceuticals (RXRX) Price Prediction
Based on a combination of financial analysis, technical indicators, and insights from alternative data, we predict that the stock price of Recursion Pharmaceuticals (RXRX), currently trading at $5.73, will... Sign up to access price prediction.
Disclaimer:
This prediction is provided for informational purposes only and does not constitute financial advice. Market conditions are subject to change, and past performance is not indicative of future results. Please conduct your own research or consult a professional before making investment decisions.
About RXRX
-
Recursion Pharmaceuticals, Inc.
-
Symbol
RXRX
-
Market
NASDAQ
-
Industry
Biotechnology
-
Market Cap
2.3B
Similar Stocks
 |
Catalyst Pharmaceuticals CPRX |
$23.45 1.1% |
5 |
 |
Inovio Pharmaceuticals INO |
$1.87 2.6% |
2 |
 |
Moderna MRNA |
$27.22 0.6% |
3 |
 |
Anavex Life Sciences AVXL |
$9.42 0.3% |
5 |
 |
BridgeBio Pharma BBIO |
$36.31 1% |
4 |
News
RXRX Alternative Data
Web Traffic
Recursion Pharmaceuticals receives an estimated 60440 monthly visitors to recursion.com.
-
Web Traffic
60440
-
Change from Previous Month
11.9%
-
3 Month Change
5.5%
-
YoY Change
5.5%
Twitter Followers
Recursion Pharmaceuticals has 14,149 Twitter Followers on its main Twitter (also known as X) account, which is up by 0.9% over the last month.
-
Twitter Followers
14149
-
Daily Change
0%
-
1 Month Change
0.9%
-
3 Month Change
5.2%
-
YoY Change
5.2%
Facebook Engagement
Recursion Pharmaceuticals has engaged 11 users via their Facebook Page over the last 7 days.
-
Facebook Engagement
11
-
Daily Change
57.1%
-
1 Month Change
21.4%
-
3 Month Change
38.9%
-
YoY Change
38.9%
Youtube Subscribers
Recursion Pharmaceuticals has 3,570 subscribers on its main Youtube channel, up by 1.7% over the last month.
-
Youtube Subscribers
3570
-
Daily Change
0.3%
-
1 Month Change
1.7%
-
3 Month Change
13.7%
-
YoY Change
13.7%
Job Postings
Recursion Pharmaceuticals has an estimated 18 open job postings, which is down -45.5% over the last month.
-
Job Postings
18
-
Daily Change
0%
-
1 Month Change
45.5%
-
3 Month Change
75.7%
-
YoY Change
75.7%
News Mentions
Recursion Pharmaceuticals was mentioned 1 times in the news yesterday.
-
News Mentions
1
-
Daily Change
0%
-
1 Month Change
0%
-
3 Month Change
66.7%
Reddit Mentions
Recursion Pharmaceuticals has been mentioned an estimated 0 times in investment subreddits on Reddit over the last 24 hours.
-
Reddit Mentions
0
-
Daily Change
0%
-
1 Month Change
0%
Business Outlook
According to employee reviews, the business outlook among employees at Recursion Pharmaceuticals is 72 out of 100 (bullish), up by 1.4% over the last month.
-
Business Outlook
72
-
Change from Previous Month
1.4%
-
3 Month Change
1.4%
-
YoY Change
1.4%
LinkedIn Employees
According to LinkedIn, Recursion Pharmaceuticals has 580 employees.
-
LinkedIn Employees
580
-
Daily Change
2%
-
1 Month Change
0%
-
3 Month Change
0%
-
YoY Change
0%
RXRX Financials
RXRX Key Metrics
-
Total Revenue
$4.5M
-
Net Income
-$178.9M
-
Earnings per Share
-$0.53
-
Free cash flow
-$117.1M
-
EBITDA
-$165.3M
-
EBITDA Ratio
-36.6533
-
Total Assets
$1.4B
RXRX 2-year Revenue & Income
RXRX 2-year Free Cash Flow
RXRX Technicals
RXRX SMA
RXRX RSI
FAQ
What's the current price of Recursion Pharmaceuticals (RXRX) Stock?
The price of an Recursion Pharmaceuticals (RXRX) share is $5.73.
What's the market cap of Recursion Pharmaceuticals?
The current market cap of Recursion Pharmaceuticals is 2.3B.
Should I buy or sell RXRX?
Recursion Pharmaceuticals shows several positive indicators, but they aren’t strong enough to warrant a buy recommendation. At its current price, Recursion Pharmaceuticals is better viewed as a hold or accumulate position while waiting for further developments.
Is Recursion Pharmaceuticals a good investment?
The current analysis of Recursion Pharmaceuticals' fundamentals, technical aspects, and alternative data insights indicates a neutral outlook on the stock. While there are promising elements in Recursion Pharmaceuticals' portfolio, the presence of equal risks and opportunities suggests that it might not drive significant gains or losses at this moment.
Is now a good time to buy Recursion Pharmaceuticals (RXRX) Stock?
Based on an analysis that includes fundamentals, technical analysis, and alternative data insights, the outlook for Recursion Pharmaceuticals stock is currently neutral, suggesting a cautious approach might be wise.
What are some stocks similar to Recursion Pharmaceuticals (RXRX) that investors often compare it to?
Recursion Pharmaceuticals (RXRX) is often compared to similar stocks such as Catalyst Pharmaceuticals, Inovio Pharmaceuticals, Moderna, Anavex Life Sciences and BridgeBio Pharma.
What is the forecast for Recursion Pharmaceuticals' stock price in 2026?
Using a mix of financial analysis, technical indicators, and alternative data, we forecast Recursion Pharmaceuticals' stock price to be around $5.53 in 2026. Starting from the current price of $5.73, this represents a 3.5% change in price, indicating a neutral outlook for the stock.
How to buy Recursion Pharmaceuticals (RXRX) Stock?
Recursion Pharmaceuticals stock is available for purchase through numerous brokerage firms, including online platforms. Investors can also buy Recursion Pharmaceuticals shares via trading apps on their smartphones or by utilizing services like robo-advisors for automated investing.